Hamano Yukako, Moriwaki Toshikazu, To Keii, Watahiki Takahisa, Yamada Takeshi, Sakashita Shingo, Hyodo Ichinosuke
Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Japan.
Department of Pathology, Faculty of Medicine, University of Tsukuba, Japan.
Intern Med. 2019 Apr 15;58(8):1087-1091. doi: 10.2169/internalmedicine.1809-18. Epub 2018 Dec 18.
The standard chemotherapies for neuroendocrine tumors (NETs) are somatostatin analog (SSA) and targeted-agents for NET G1/G2 and platinum-based chemotherapy for neuroendocrine carcinoma (NEC), classified according to the WHO criteria of 2010. We report a case of NET, in which tumors were successfully treated with platinum-containing chemotherapy after remarkable progression with SSA. A 46-year-old man with multiple lymph nodes and liver metastases of unknown primary origin was diagnosed with NET G2 based on the examination of a biopsy specimen. His tumors were stable with SSA for a year, but rapidly became enlarged. A second biopsy revealed NEC. He received cisplatin plus etoposide, and his tumors showed a marked reduction in size.
根据2010年世界卫生组织标准，神经内分泌肿瘤（NETs）的标准化疗方案是：NET G1/G2采用生长抑素类似物（SSA）和靶向药物，神经内分泌癌（NEC）采用铂类化疗。我们报告一例NET病例，该患者在使用SSA治疗显著进展后，采用含铂化疗成功治疗。一名46岁男性，多发淋巴结及肝脏转移，原发灶不明，经活检标本检查诊断为NET G2。其肿瘤用SSA治疗一年病情稳定，但随后迅速增大。再次活检显示为NEC。他接受了顺铂加依托泊苷治疗，肿瘤大小显著缩小。
